Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors
10.3760/cma.j.issn.1671-0274.2014.04.006
- VernacularTitle:胃肠间质瘤靶向治疗耐药机制及治疗策略新进展
- Author:
Yinan SHI
1
;
Xiaobo LIANG
Author Information
1. 山西省肿瘤医院微创外科
- Keywords:
Gastrointestinal stromal tumors;
Targeted therapy;
Imatinib resistance
- From:
Chinese Journal of Gastrointestinal Surgery
2014;(4):321-325
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Most of these stromal tumors are characterized by mutations in the KTT or platelet-derived growth factor receptorα (PDGFRA) genes, resulting in the constitutive activation of tyrosine kinase signaling. Tyrosine kinase inhibitors (TKI), such as imatinib and sunitinib, provide the standard first-line and second-line therapy for patients with metastatic or unresectable GIST. Imatinib resistance has been a challenging problem in clinical practice and raised great concern. This review introduces the underlying mechanisms of imatinib resistance and advances of treatment strategies. Reasonable individual treatment with the guidance of molecular biology is promising to improve the efficacy and the quality of life for GIST patients.
